Utrecht, Netherlands – 13 June 2025 – The EuroHeartPath project, officially launched under the Horizon Europe Innovative Health Initiative Joint Undertaking (IHI-JU), brings together 35 leading academic, clinical, public health, industry, and societal partners from across Europe. With a significant €27 million budget spanning a five-year timeline, EuroHeartPath is set to radically transform cardiovascular care by mapping, comparing, and optimizing care pathways throughout the continuum of heart disease.

Despite significant advancements, cardiovascular disease (CVD) remains Europe's leading cause of death and disability. EuroHeartPath addresses this critical challenge through an innovative pan-European approach, fostering cross-border learning, collaboration, and integration. The project comprises 18 pioneering pathfinder studies structured around four core technological areas: artificial intelligence (AI) and machine learning, digital health integration, point-of-care diagnostics, and advanced robotic technologies.

Examples of pathfinder studies include the PACEVALUE pathfinder, that addresses the significant gaps in the management of cardiovascular implantable electronic devices (CIEDs) for arrhythmias and heart failure; and the EXPLAIN pathfinder that leverages AI to enhance the interpretation of electrocardiograms (ECGs), aiming to overcome the limitations of current computerized ECG interpretations and expand on clinical utility.

Central to EuroHeartPath are patient-centeredness and equity, with dedicated efforts aimed at improving outcomes specifically for underserved groups, and promoting personalized, value-based healthcare.

Prof. Pim van der Harst, Coordinator and Head of Cardiology at UMC Utrecht, stated: "EuroHeartPath represents a unique chance to not only analyse cardiovascular care across Europe but fundamentally redesign it. This project leverages data, technology, and international collaboration to create a dynamic, learning healthcare system that can significantly enhance care quality, patient outcomes, and overall health system resilience."

A Unique Pan-European and Multi-Sector Collaboration

The EuroHeartPath consortium brings together diverse expertise from hospitals, academic institutions, technology innovators, policymakers, and patient advocacy groups. Through this unique collaboration, partners aim to bridge the gap between innovation and clinical practice, ensuring that breakthroughs quickly translate into practical, widespread benefits for European citizens at risk of or living with heart disease.

A Great Opportunity for Cordys Analytics

Cordys Analytics is proud to be part of the EuroHeartPath consortium. Our specific contribution involves developing AI-driven ECG diagnostics for early detection and personalized treatment of heart disease, and enhancing remote monitoring using wearable technology. Our participation emphasizes the advancement of AI-driven cardiovascular diagnostics within the Dutch and broader European healthcare systems, fostering earlier detection, more precise treatment, and improved accessibility. Ultimately, we aim to enhance the quality, efficiency, and equity of cardiovascular healthcare delivery and outcomes.

John van den Berg commented: “Our participation in EuroHeartPath highlights Cordys Analytics’ deep commitment to advancing cardiovascular health across Europe. By contributing our expertise in cutting-edge AI-powered ECG diagnostics, we aim to help transform the way heart disease is detected and managed. We’re proud to join this ambitious initiative and look forward to driving meaningful innovation in collaboration with our European partners.”

About EuroHeartPath

Funded by the Innovative Health Initiative Joint Undertaking (IHI-JU), EuroHeartPath unites prominent stakeholders including UMC Utrecht, Amsterdam UMC, London School of Economics and Political Science, Technische Universiteit Eindhoven, Deutsches Herzzentrum München, Insel Gruppe AG (University Hospital Bern), Servicio Madrileño de Salud (SERMAS), Assistance Publique Hôpitaux de Paris (APHP), RCF@ICPS, Charité - Universitätsmedizin Berlin, Universiteit Maastricht, Philips Medical Systems Nederland BV, Philips France Commercial, Medtronic Ibérica SA, Medtronic GmbH, AstraZeneca UK Limited, Boston Scientific Netherlands BV, IQVIA Solutions Belgium BV, Novo Nordisk A/S, Novartis Pharma BV, Amarin Pharmaceuticals Ireland Limited, Vintura BV, Zeesta Labs, Corbotics BV, Chateau Sante, Van Vliet Diagnostics BV, Cordys Analytics, Medicine Men BV, Stichting Cardiologie Centra Nederland, Heart for Health ICT BV, Cito Diagnostics BV, Discovery XD One SRL, Stichting WONCA Europe, European Society of Cardiology (ESC), European Pathway Association (EPA), Outcomes'10 SL, European Public Health Association (EUPHA). The initiative spans multiple European countries, aiming to set new standards in cardiovascular care.

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194785. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe.